Q-omics provides the consensus-scored LY6G6F-LY6G6D profile across patient tissues and cancer cell-line models. LY6G6F-LY6G6D expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LY6G6F-LY6G6D is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, LY6G6F-LY6G6D RNA expression shows 9,355 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where LY6G6F-LY6G6D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6G6F-LY6G6D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6G6F-LY6G6D survival associations across molecular data types. LY6G6F-LY6G6D RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6G6F-LY6G6D RNA expression–survival associations across cancer types. High LY6G6F-LY6G6D expression shows unfavorable associations in KICH, LGG, KIRC, ACC, MESO and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LY6G6F-LY6G6D RNA expression.
This table summarizes LY6G6F-LY6G6D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LY6G6F-LY6G6D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6G6F-LY6G6D shows lower tumor expression in BLCA, LUAD, THCA, HNSC and KIRC and higher tumor expression in COAD. The COAD box plot shows higher LY6G6F-LY6G6D RNA expression in tumor versus normal tissue (log2 FC = +3.098, t-test p < 0.001).
This table shows molecular features associated with LY6G6F-LY6G6D in patient tissues and cancer cell lines. In patient samples, LY6G6F-LY6G6D shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
